Our target discovery and validation group has a proven track record in identifying disease-relevant targets across diverse classes including kinases, GPCRs, enzymes, orphan receptors, and transporters. Capabilities include: Comprehensive biochemical and genetic validation; Disease-linked target selection using cellular and molecular assays; 2–6 month validation cycles, ensuring efficient project advancement. Comprehensive and early target validation is essential in establishing a strong link between target manipulation and its effectiveness in treating the disease, which greatly enhances the likelihood of success in clinical trials. Once a target reaches a satisfactory level of validation and connection to the disease, the project progresses to the hit identification phase.
Compiled from https://www.jubilantbiosys.com
